What does this source bring?
ATOM showed slower refractive progression and ocular axis increase with atropine 1% than with placebo.
One randomly selected eye was treated; Asian population. We do not transfer the effects and effectiveness of this concentration directly to low concentrations.
CLAIM-ATOMScope of testing and verification
- The role of the record
- Source of the claim
- Population
- 6–12 children with myopia, Singapore
- N
- 400
- Geography
- Singapore
- Observation (months)
- 24
- Comparator
- Placebo
- Result
- ATOM showed slower refractive progression and ocular axis increase with atropine 1% than with placebo.
- Safety
- Mydriasis and decreased accommodation require clinical consideration.
- Device/structure
- Not applicable / not determined within the verified range
- Publisher of the publication
- Elsevier BV
- Financing
- National Medical Research Council (Crossref metadata; may not include all forms of support).
- Conflicts of interest
- Not determined within the proven range. The absence of confirmation does not mean the absence of conflict.
- DOI
- 10.1016 /j.ophtha. 2006.05.062
- PMID
- 16996612
- What was checked
- Bibliographic metadata and abstract in Europe PMC / PubMed; Crossref metadata
- Date of verification
- 2026-09-09
This is the editorial card of the publication. The description does not replace the full text, supplementary data or instructions for a specific device.